



Sustained Release Injectables Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-20	141	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

Description

The global Sustained Release Injectables market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Sustained Release Injectables market is projected to increase from US\$ million in 2026 to US\$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Sustained Release Injectables market is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Sustained Release Injectables market is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Sustained Release Injectables include Sanofi, Novartis, Merck, Luye Pharma Group, Roche, Livzon Pharm, Eli Lilly, AstraZeneca and Xbrane Biopharma, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Sustained Release Injectables market in terms of revenue (US\$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US\$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Sustained Release Injectables.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Sustained Release Injectables Market by Company

Sanofi

Novartis

Merck

Luye Pharma Group

Roche
Livzon Pharm
Eli Lilly
AstraZeneca
Xbrane Biopharma
Taiwan Liposome Company (TLC)
Recipharm AB
PhaseBio Pharmaceuticals
Pacira
OctoPlus
Oakwood Laboratories/PharmaSophia
NanOlogy
Janssen
Ipsen
InnoCore Pharmaceuticals
Enzon
Durect
Critical Pharmaceuticals
Camurus
Biomarin
Avadel
Aurobindo
Ascendis Pharma
AntriaBio
Amylin Pharmaceuticals
Alkermes

Sustained Release Injectables Segment by Type

Gels
Microparticles
Implants

Sustained Release Injectables Segment by Application

Oncology
CNS
Acromegaly
Ophthalmology
Diabetes
Reproductive Health
Rheumatology
Leukemia
Others

Sustained Release Injectables Segment by Region

North America
United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sustained Release Injectables market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sustained Release Injectables and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sustained Release Injectables.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4:

Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5:

Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6:

Detailed analysis of Sustained Release Injectables companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Sustained Release Injectables by Type
 - 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
 - 2.2.2 Gels
 - 2.2.3 Microparticles
 - 2.2.4 Implants
- 2.3 Sustained Release Injectables by Application
 - 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.3.2 Oncology
 - 2.3.3 CNS
 - 2.3.4 Acromegaly
 - 2.3.5 Ophthalmology
 - 2.3.6 Diabetes
 - 2.3.7 Reproductive Health
 - 2.3.8 Rheumatology
 - 2.3.9 Leukemia
 - 2.3.10 Others
- 2.4 Assumptions and Limitations

3 Sustained Release Injectables Breakdown Data by Type

- 3.1 Global Sustained Release Injectables Historic Market Size by Type (2021-2026)
- 3.2 Global Sustained Release Injectables Forecasted Market Size by Type (2027-2032)

4 Sustained Release Injectables Breakdown Data by Application

- 4.1 Global Sustained Release Injectables Historic Market Size by Application (2021-2026)
- 4.2 Global Sustained Release Injectables Forecasted Market Size by Application (2027-2032)

5 Global Growth Trends

- 5.1 Global Sustained Release Injectables Market Perspective (2021-2032)
- 5.2 Global Sustained Release Injectables Growth Trends by Region
 - 5.2.1 Global Sustained Release Injectables Market Size by Region: 2021 VS 2025 VS 2032
 - 5.2.2 Sustained Release Injectables Historic Market Size by Region (2021-2026)
 - 5.2.3 Sustained Release Injectables Forecasted Market Size by Region (2027-2032)
- 5.3 Sustained Release Injectables Market Dynamics
 - 5.3.1 Sustained Release Injectables Industry Trends
 - 5.3.2 Sustained Release Injectables Market Drivers

5.3.3 Sustained Release Injectables Market Challenges

5.3.4 Sustained Release Injectables Market Restraints

6 Market Competitive Landscape by Players

6.1 Global Top Sustained Release Injectables Players by Revenue

6.1.1 Global Top Sustained Release Injectables Players by Revenue (2021-2026)

6.1.2 Global Sustained Release Injectables Revenue Market Share by Players (2021-2026)

6.2 Global Sustained Release Injectables Industry Players Ranking, 2023 VS 2024 VS 2025

6.3 Global Key Players of Sustained Release Injectables Head Office and Area Served

6.4 Global Sustained Release Injectables Players, Product Type & Application

6.5 Global Sustained Release Injectables Manufacturers Established Date

6.6 Global Sustained Release Injectables Market CR5 and HHI

6.7 Global Players Mergers & Acquisition

7 North America

7.1 North America Sustained Release Injectables Market Size (2021-2032)

7.2 North America Sustained Release Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032

7.3 North America Sustained Release Injectables Market Size by Country (2021-2026)

7.4 North America Sustained Release Injectables Market Size by Country (2027-2032)

7.5 United States

7.5 United States

7.6 Canada

7.7 Mexico

8 Europe

8.1 Europe Sustained Release Injectables Market Size (2021-2032)

8.2 Europe Sustained Release Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032

8.3 Europe Sustained Release Injectables Market Size by Country (2021-2026)

8.4 Europe Sustained Release Injectables Market Size by Country (2027-2032)

8.5 Germany

8.6 France

8.7 U.K.

8.8 Italy

8.9 Spain

8.10 Russia

8.11 Netherlands

8.12 Nordic Countries

9 Asia-Pacific

9.1 Asia-Pacific Sustained Release Injectables Market Size (2021-2032)

9.2 Asia-Pacific Sustained Release Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032

9.3 Asia-Pacific Sustained Release Injectables Market Size by Country (2021-2026)

9.4 Asia-Pacific Sustained Release Injectables Market Size by Country (2027-2032)

9.5 China

9.6 Japan

9.7 South Korea

9.8 India

9.9 Australia

9.10 China Taiwan

9.11 Southeast Asia

10 South America

- 10.1 South America Sustained Release Injectables Market Size (2021-2032)
 - 10.2 South America Sustained Release Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032
 - 10.3 South America Sustained Release Injectables Market Size by Country (2021-2026)
 - 10.4 South America Sustained Release Injectables Market Size by Country (2027-2032)
 - 10.5 Brazil
 - 10.6 Argentina
 - 10.7 Chile
 - 10.8 Colombia
 - 10.9 Peru
-

11 Middle East & Africa

- 11.1 Middle East & Africa Sustained Release Injectables Market Size (2021-2032)
 - 11.2 Middle East & Africa Sustained Release Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032
 - 11.3 Middle East & Africa Sustained Release Injectables Market Size by Country (2021-2026)
 - 11.4 Middle East & Africa Sustained Release Injectables Market Size by Country (2027-2032)
 - 11.5 Saudi Arabia
 - 11.6 Israel
 - 11.7 United Arab Emirates
 - 11.8 Turkey
 - 11.9 Iran
 - 11.10 Egypt
-

12 Players Profiled

- 12.1 Sanofi
 - 12.1.1 Sanofi Company Information
 - 12.1.2 Sanofi Business Overview
 - 12.1.3 Sanofi Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.1.4 Sanofi Sustained Release Injectables Product Portfolio
 - 12.1.5 Sanofi Recent Developments
- 12.2 Novartis
 - 12.2.1 Novartis Company Information
 - 12.2.2 Novartis Business Overview
 - 12.2.3 Novartis Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.2.4 Novartis Sustained Release Injectables Product Portfolio
 - 12.2.5 Novartis Recent Developments
- 12.3 Merck
 - 12.3.1 Merck Company Information
 - 12.3.2 Merck Business Overview
 - 12.3.3 Merck Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.3.4 Merck Sustained Release Injectables Product Portfolio
 - 12.3.5 Merck Recent Developments
- 12.4 Luye Pharma Group
 - 12.4.1 Luye Pharma Group Company Information
 - 12.4.2 Luye Pharma Group Business Overview
 - 12.4.3 Luye Pharma Group Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.4.4 Luye Pharma Group Sustained Release Injectables Product Portfolio
 - 12.4.5 Luye Pharma Group Recent Developments
- 12.5 Roche

- 12.5.1 Roche Company Information
- 12.5.2 Roche Business Overview
- 12.5.3 Roche Revenue in Sustained Release Injectables Business (2021-2026)
- 12.5.4 Roche Sustained Release Injectables Product Portfolio
- 12.5.5 Roche Recent Developments
- 12.6 Livzon Pharm
 - 12.6.1 Livzon Pharm Company Information
 - 12.6.2 Livzon Pharm Business Overview
 - 12.6.3 Livzon Pharm Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.6.4 Livzon Pharm Sustained Release Injectables Product Portfolio
 - 12.6.5 Livzon Pharm Recent Developments
- 12.7 Eli Lilly
 - 12.7.1 Eli Lilly Company Information
 - 12.7.2 Eli Lilly Business Overview
 - 12.7.3 Eli Lilly Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.7.4 Eli Lilly Sustained Release Injectables Product Portfolio
 - 12.7.5 Eli Lilly Recent Developments
- 12.8 AstraZeneca
 - 12.8.1 AstraZeneca Company Information
 - 12.8.2 AstraZeneca Business Overview
 - 12.8.3 AstraZeneca Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.8.4 AstraZeneca Sustained Release Injectables Product Portfolio
 - 12.8.5 AstraZeneca Recent Developments
- 12.9 Xbrane Biopharma
 - 12.9.1 Xbrane Biopharma Company Information
 - 12.9.2 Xbrane Biopharma Business Overview
 - 12.9.3 Xbrane Biopharma Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.9.4 Xbrane Biopharma Sustained Release Injectables Product Portfolio
 - 12.9.5 Xbrane Biopharma Recent Developments
- 12.10 Taiwan Liposome Company (TLC)
 - 12.10.1 Taiwan Liposome Company (TLC) Company Information
 - 12.10.2 Taiwan Liposome Company (TLC) Business Overview
 - 12.10.3 Taiwan Liposome Company (TLC) Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.10.4 Taiwan Liposome Company (TLC) Sustained Release Injectables Product Portfolio
 - 12.10.5 Taiwan Liposome Company (TLC) Recent Developments
- 12.11 Recipharm AB
 - 12.11.1 Recipharm AB Company Information
 - 12.11.2 Recipharm AB Business Overview
 - 12.11.3 Recipharm AB Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.11.4 Recipharm AB Sustained Release Injectables Product Portfolio
 - 12.11.5 Recipharm AB Recent Developments
- 12.12 PhaseBio Pharmaceuticals
 - 12.12.1 PhaseBio Pharmaceuticals Company Information
 - 12.12.2 PhaseBio Pharmaceuticals Business Overview
 - 12.12.3 PhaseBio Pharmaceuticals Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.12.4 PhaseBio Pharmaceuticals Sustained Release Injectables Product Portfolio
 - 12.12.5 PhaseBio Pharmaceuticals Recent Developments
- 12.13 Pacira

- 12.13.1 Pacira Company Information
- 12.13.2 Pacira Business Overview
- 12.13.3 Pacira Revenue in Sustained Release Injectables Business (2021-2026)
- 12.13.4 Pacira Sustained Release Injectables Product Portfolio
- 12.13.5 Pacira Recent Developments
- 12.14 OctoPlus
 - 12.14.1 OctoPlus Company Information
 - 12.14.2 OctoPlus Business Overview
 - 12.14.3 OctoPlus Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.14.4 OctoPlus Sustained Release Injectables Product Portfolio
 - 12.14.5 OctoPlus Recent Developments
- 12.15 Oakwood Laboratories/PharmaSophia
 - 12.15.1 Oakwood Laboratories/PharmaSophia Company Information
 - 12.15.2 Oakwood Laboratories/PharmaSophia Business Overview
 - 12.15.3 Oakwood Laboratories/PharmaSophia Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.15.4 Oakwood Laboratories/PharmaSophia Sustained Release Injectables Product Portfolio
 - 12.15.5 Oakwood Laboratories/PharmaSophia Recent Developments
- 12.16 NanOlogy
 - 12.16.1 NanOlogy Company Information
 - 12.16.2 NanOlogy Business Overview
 - 12.16.3 NanOlogy Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.16.4 NanOlogy Sustained Release Injectables Product Portfolio
 - 12.16.5 NanOlogy Recent Developments
- 12.17 Janssen
 - 12.17.1 Janssen Company Information
 - 12.17.2 Janssen Business Overview
 - 12.17.3 Janssen Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.17.4 Janssen Sustained Release Injectables Product Portfolio
 - 12.17.5 Janssen Recent Developments
- 12.18 Ipsen
 - 12.18.1 Ipsen Company Information
 - 12.18.2 Ipsen Business Overview
 - 12.18.3 Ipsen Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.18.4 Ipsen Sustained Release Injectables Product Portfolio
 - 12.18.5 Ipsen Recent Developments
- 12.19 InnoCore Pharmaceuticals
 - 12.19.1 InnoCore Pharmaceuticals Company Information
 - 12.19.2 InnoCore Pharmaceuticals Business Overview
 - 12.19.3 InnoCore Pharmaceuticals Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.19.4 InnoCore Pharmaceuticals Sustained Release Injectables Product Portfolio
 - 12.19.5 InnoCore Pharmaceuticals Recent Developments
- 12.20 Enzon
 - 12.20.1 Enzon Company Information
 - 12.20.2 Enzon Business Overview
 - 12.20.3 Enzon Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.20.4 Enzon Sustained Release Injectables Product Portfolio
 - 12.20.5 Enzon Recent Developments
- 12.21 Durect

- 12.21.1 Durect Company Information
- 12.21.2 Durect Business Overview
- 12.21.3 Durect Revenue in Sustained Release Injectables Business (2021-2026)
- 12.21.4 Durect Sustained Release Injectables Product Portfolio
- 12.21.5 Durect Recent Developments
- 12.22 Critical Pharmaceuticals
 - 12.22.1 Critical Pharmaceuticals Company Information
 - 12.22.2 Critical Pharmaceuticals Business Overview
 - 12.22.3 Critical Pharmaceuticals Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.22.4 Critical Pharmaceuticals Sustained Release Injectables Product Portfolio
 - 12.22.5 Critical Pharmaceuticals Recent Developments
- 12.23 Camurus
 - 12.23.1 Camurus Company Information
 - 12.23.2 Camurus Business Overview
 - 12.23.3 Camurus Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.23.4 Camurus Sustained Release Injectables Product Portfolio
 - 12.23.5 Camurus Recent Developments
- 12.24 Biomarin
 - 12.24.1 Biomarin Company Information
 - 12.24.2 Biomarin Business Overview
 - 12.24.3 Biomarin Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.24.4 Biomarin Sustained Release Injectables Product Portfolio
 - 12.24.5 Biomarin Recent Developments
- 12.25 Avadel
 - 12.25.1 Avadel Company Information
 - 12.25.2 Avadel Business Overview
 - 12.25.3 Avadel Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.25.4 Avadel Sustained Release Injectables Product Portfolio
 - 12.25.5 Avadel Recent Developments
- 12.26 Aurobindo
 - 12.26.1 Aurobindo Company Information
 - 12.26.2 Aurobindo Business Overview
 - 12.26.3 Aurobindo Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.26.4 Aurobindo Sustained Release Injectables Product Portfolio
 - 12.26.5 Aurobindo Recent Developments
- 12.27 Ascendis Pharma
 - 12.27.1 Ascendis Pharma Company Information
 - 12.27.2 Ascendis Pharma Business Overview
 - 12.27.3 Ascendis Pharma Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.27.4 Ascendis Pharma Sustained Release Injectables Product Portfolio
 - 12.27.5 Ascendis Pharma Recent Developments
- 12.28 AntriaBio
 - 12.28.1 AntriaBio Company Information
 - 12.28.2 AntriaBio Business Overview
 - 12.28.3 AntriaBio Revenue in Sustained Release Injectables Business (2021-2026)
 - 12.28.4 AntriaBio Sustained Release Injectables Product Portfolio
 - 12.28.5 AntriaBio Recent Developments
- 12.29 Amylin Pharmaceuticals

12.29.1 Amylin Pharmaceuticals Company Information

12.29.2 Amylin Pharmaceuticals Business Overview

12.29.3 Amylin Pharmaceuticals Revenue in Sustained Release Injectables Business (2021-2026)

12.29.4 Amylin Pharmaceuticals Sustained Release Injectables Product Portfolio

12.29.5 Amylin Pharmaceuticals Recent Developments

12.30 Alkermes

12.30.1 Alkermes Company Information

12.30.2 Alkermes Business Overview

12.30.3 Alkermes Revenue in Sustained Release Injectables Business (2021-2026)

12.30.4 Alkermes Sustained Release Injectables Product Portfolio

12.30.5 Alkermes Recent Developments

13 Report Conclusion

14 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Sustained Release Injectables Market Size by Type (2021-2026) & (US\$ Million)
- Table 6: Global Sustained Release Injectables Revenue Market Share by Type (2021-2026)
- Table 7: Global Sustained Release Injectables Forecasted Market Size by Type (2027-2032) & (US\$ Million)
- Table 8: Global Sustained Release Injectables Revenue Market Share by Type (2027-2032)
- Table 9: Global Sustained Release Injectables Market Size by Application (2021-2026) & (US\$ Million)
- Table 10: Global Sustained Release Injectables Revenue Market Share by Application (2021-2026)
- Table 11: Global Sustained Release Injectables Forecasted Market Size by Application (2027-2032) & (US\$ Million)
- Table 12: Global Sustained Release Injectables Revenue Market Share by Application (2027-2032)
- Table 13: Global Sustained Release Injectables Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 14: Global Sustained Release Injectables Market Size by Region (2021-2026) & (US\$ Million)
- Table 15: Global Sustained Release Injectables Market Share by Region (2021-2026)
- Table 16: Global Sustained Release Injectables Forecasted Market Size by Region (2027-2032) & (US\$ Million)
- Table 17: Global Sustained Release Injectables Market Share by Region (2027-2032)
- Table 18: Sustained Release Injectables Industry Trends
- Table 19: Sustained Release Injectables Industry Drivers
- Table 20: Sustained Release Injectables Industry Opportunities and Challenges
- Table 21: Sustained Release Injectables Market Restraints
- Table 22: Global Top Sustained Release Injectables Players by Revenue (US\$ Million) & (2021-2026)
- Table 23: Global Sustained Release Injectables Revenue Market Share by Players (2021-2026)
- Table 24: Global Sustained Release Injectables Industry Players Ranking, 2024 VS 2025 VS 2026
- Table 25: Global Key Players of Sustained Release Injectables, Headquarters and Area Served
- Table 26: Global Sustained Release Injectables Players, Product Type & Application
- Table 27: Global Players Market Concentration Ratio (CR5 and HHI)
- Table 28: Global Sustained Release Injectables by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 29: Players Mergers & Acquisitions, Expansion Plans
- Table 30: North America Sustained Release Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 31: North America Sustained Release Injectables Market Size by Country (2021-2026) & (US\$ Million)
- Table 32: North America Sustained Release Injectables Market Size by Country (2027-2032) & (US\$ Million)
- Table 33: Europe Sustained Release Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 34: Europe Sustained Release Injectables Market Size by Country (2021-2026) & (US\$ Million)
- Table 35: Europe Sustained Release Injectables Market Size by Country (2027-2032) & (US\$ Million)
- Table 36: Asia Pacific Sustained Release Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 37: Asia Pacific Sustained Release Injectables Market Size by Region (2021-2026) & (US\$ Million)
- Table 38: Asia Pacific Sustained Release Injectables Market Size by Country (2027-2032) & (US\$ Million)
- Table 39: South America Sustained Release Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 40: South America Sustained Release Injectables Market Size by Country (2021-2026) & (US\$ Million)
- Table 41: South America Sustained Release Injectables Market Size by Country (2027-2032) & (US\$ Million)
- Table 42: Middle East & Africa Sustained Release Injectables Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 43: Middle East & Africa Sustained Release Injectables Market Size by Country (2021-2026) & (US\$ Million)
- Table 44: Middle East & Africa Sustained Release Injectables Market Size by Country (2027-2032) & (US\$ Million)
- Table 45: Sanofi Company Information
- Table 46: Sanofi Business Overview
- Table 47: Sanofi Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 48: Sanofi Sustained Release Injectables Product Portfolio
- Table 49: Sanofi Recent Developments
- Table 50: Novartis Company Information
- Table 51: Novartis Business Overview
- Table 52: Novartis Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 53: Novartis Sustained Release Injectables Product Portfolio
- Table 54: Novartis Recent Developments

- Table 55: Merck Company Information
- Table 56: Merck Business Overview
- Table 57: Merck Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 58: Merck Sustained Release Injectables Product Portfolio
- Table 59: Merck Recent Developments
- Table 60: Luye Pharma Group Company Information
- Table 61: Luye Pharma Group Business Overview
- Table 62: Luye Pharma Group Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 63: Luye Pharma Group Sustained Release Injectables Product Portfolio
- Table 64: Luye Pharma Group Recent Developments
- Table 65: Roche Company Information
- Table 66: Roche Business Overview
- Table 67: Roche Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 68: Roche Sustained Release Injectables Product Portfolio
- Table 69: Roche Recent Developments
- Table 70: Livzon Pharm Company Information
- Table 71: Livzon Pharm Business Overview
- Table 72: Livzon Pharm Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 73: Livzon Pharm Sustained Release Injectables Product Portfolio
- Table 74: Livzon Pharm Recent Developments
- Table 75: Eli Lilly Company Information
- Table 76: Eli Lilly Business Overview
- Table 77: Eli Lilly Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 78: Eli Lilly Sustained Release Injectables Product Portfolio
- Table 79: Eli Lilly Recent Developments
- Table 80: AstraZeneca Company Information
- Table 81: AstraZeneca Business Overview
- Table 82: AstraZeneca Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 83: AstraZeneca Sustained Release Injectables Product Portfolio
- Table 84: AstraZeneca Recent Developments
- Table 85: Xbrane Biopharma Company Information
- Table 86: Xbrane Biopharma Business Overview
- Table 87: Xbrane Biopharma Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 88: Xbrane Biopharma Sustained Release Injectables Product Portfolio
- Table 89: Xbrane Biopharma Recent Developments
- Table 90: Taiwan Liposome Company (TLC) Company Information
- Table 91: Taiwan Liposome Company (TLC) Business Overview
- Table 92: Taiwan Liposome Company (TLC) Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 93: Taiwan Liposome Company (TLC) Sustained Release Injectables Product Portfolio
- Table 94: Taiwan Liposome Company (TLC) Recent Developments
- Table 95: Recipharm AB Company Information
- Table 96: Recipharm AB Business Overview
- Table 97: Recipharm AB Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 98: Recipharm AB Sustained Release Injectables Product Portfolio
- Table 99: Recipharm AB Recent Developments
- Table 100: PhaseBio Pharmaceuticals Company Information
- Table 101: PhaseBio Pharmaceuticals Business Overview
- Table 102: PhaseBio Pharmaceuticals Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 103: PhaseBio Pharmaceuticals Sustained Release Injectables Product Portfolio
- Table 104: PhaseBio Pharmaceuticals Recent Developments
- Table 105: Pacira Company Information
- Table 106: Pacira Business Overview
- Table 107: Pacira Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 108: Pacira Sustained Release Injectables Product Portfolio
- Table 109: Pacira Recent Developments
- Table 110: OctoPlus Company Information
- Table 111: OctoPlus Business Overview
- Table 112: OctoPlus Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 113: OctoPlus Sustained Release Injectables Product Portfolio
- Table 114: OctoPlus Recent Developments
- Table 115: Oakwood Laboratories/PharmaSophia Company Information
- Table 116: Oakwood Laboratories/PharmaSophia Business Overview
- Table 117: Oakwood Laboratories/PharmaSophia Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 118: Oakwood Laboratories/PharmaSophia Sustained Release Injectables Product Portfolio

- Table 119: Oakwood Laboratories/PharmaSophia Recent Developments
- Table 120: NanOlogy Company Information
- Table 121: NanOlogy Business Overview
- Table 122: NanOlogy Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 123: NanOlogy Sustained Release Injectables Product Portfolio
- Table 124: NanOlogy Recent Developments
- Table 125: Janssen Company Information
- Table 126: Janssen Business Overview
- Table 127: Janssen Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 128: Janssen Sustained Release Injectables Product Portfolio
- Table 129: Janssen Recent Developments
- Table 130: Ipsen Company Information
- Table 131: Ipsen Business Overview
- Table 132: Ipsen Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 133: Ipsen Sustained Release Injectables Product Portfolio
- Table 134: Ipsen Recent Developments
- Table 135: InnoCore Pharmaceuticals Company Information
- Table 136: InnoCore Pharmaceuticals Business Overview
- Table 137: InnoCore Pharmaceuticals Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 138: InnoCore Pharmaceuticals Sustained Release Injectables Product Portfolio
- Table 139: InnoCore Pharmaceuticals Recent Developments
- Table 140: Enzon Company Information
- Table 141: Enzon Business Overview
- Table 142: Enzon Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 143: Enzon Sustained Release Injectables Product Portfolio
- Table 144: Enzon Recent Developments
- Table 145: Durect Company Information
- Table 146: Durect Business Overview
- Table 147: Durect Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 148: Durect Sustained Release Injectables Product Portfolio
- Table 149: Durect Recent Developments
- Table 150: Critical Pharmaceuticals Company Information
- Table 151: Critical Pharmaceuticals Business Overview
- Table 152: Critical Pharmaceuticals Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 153: Critical Pharmaceuticals Sustained Release Injectables Product Portfolio
- Table 154: Critical Pharmaceuticals Recent Developments
- Table 155: Camurus Company Information
- Table 156: Camurus Business Overview
- Table 157: Camurus Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 158: Camurus Sustained Release Injectables Product Portfolio
- Table 159: Camurus Recent Developments
- Table 160: Biomarin Company Information
- Table 161: Biomarin Business Overview
- Table 162: Biomarin Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 163: Biomarin Sustained Release Injectables Product Portfolio
- Table 164: Biomarin Recent Developments
- Table 165: Avadel Company Information
- Table 166: Avadel Business Overview
- Table 167: Avadel Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 168: Avadel Sustained Release Injectables Product Portfolio
- Table 169: Avadel Recent Developments
- Table 170: Aurobindo Company Information
- Table 171: Aurobindo Business Overview
- Table 172: Aurobindo Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 173: Aurobindo Sustained Release Injectables Product Portfolio
- Table 174: Aurobindo Recent Developments
- Table 175: Ascendis Pharma Company Information
- Table 176: Ascendis Pharma Business Overview
- Table 177: Ascendis Pharma Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 178: Ascendis Pharma Sustained Release Injectables Product Portfolio
- Table 179: Ascendis Pharma Recent Developments
- Table 180: AntriaBio Company Information
- Table 181: AntriaBio Business Overview
- Table 182: AntriaBio Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 183: AntriaBio Sustained Release Injectables Product Portfolio

- Table 184: AntriaBio Recent Developments
- Table 185: Amylin Pharmaceuticals Company Information
- Table 186: Amylin Pharmaceuticals Business Overview
- Table 187: Amylin Pharmaceuticals Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 188: Amylin Pharmaceuticals Sustained Release Injectables Product Portfolio
- Table 189: Amylin Pharmaceuticals Recent Developments
- Table 190: Alkermes Company Information
- Table 191: Alkermes Business Overview
- Table 192: Alkermes Revenue in Sustained Release Injectables Business (2021-2026) & (US\$ Million)
- Table 193: Alkermes Sustained Release Injectables Product Portfolio
- Table 194: Alkermes Recent Developments
- Table 195: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Sustained Release Injectables Product Image
- Figure 5: Global Sustained Release Injectables Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 6: Global Sustained Release Injectables Market Share by Type: 2025 VS 2032
- Figure 7: Gels Product
- Figure 8: Microparticles Product
- Figure 9: Implants Product
- Figure 10: Global Sustained Release Injectables Market Size by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 11: Global Sustained Release Injectables Market Share by Application: 2025 VS 2032
- Figure 12: Oncology Product
- Figure 13: CNS Product
- Figure 14: Acromegaly Product
- Figure 15: Ophthalmology Product
- Figure 16: Diabetes Product
- Figure 17: Reproductive Health Product
- Figure 18: Rheumatology Product
- Figure 19: Leukemia Product
- Figure 20: Others Product
- Figure 21: Global Sustained Release Injectables Market Size (US\$ Million), Year-over-Year: 2021-2032
- Figure 22: Global Sustained Release Injectables Market Size, (US\$ Million), 2021 VS 2025 VS 2032
- Figure 23: Global Sustained Release Injectables Market Share by Region: 2025 VS 2032
- Figure 24: Global Sustained Release Injectables Market Share by Players in 2025
- Figure 25: Global Sustained Release Injectables Manufacturers Established Date
- Figure 26: Global Top 5 and 10 Sustained Release Injectables Players Market Share by Revenue in 2025
- Figure 27: Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 28: North America Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 29: North America Sustained Release Injectables Market Share by Country (2021-2032)
- Figure 30: United States Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 31: Canada Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 32: Mexico Sustained Release Injectables Market Share by Country (2021-2032)
- Figure 33: Europe Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 34: Europe Sustained Release Injectables Market Share by Country (2021-2032)
- Figure 35: Germany Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 36: France Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 37: U.K. Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 38: Italy Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 39: Spain Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 40: Russia Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 41: Netherlands Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 42: Nordic Countries Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 43: Asia-Pacific Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 44: Asia-Pacific Sustained Release Injectables Market Share by Country (2021-2032)
- Figure 45: China Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 46: Japan Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 47: South Korea Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 48: India Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 49: India Sustained Release Injectables Market Share by Country (2021-2032)

- Figure 50: Australia Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 51: China Taiwan Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 52: Southeast Asia Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 53: South America Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 54: South America Sustained Release Injectables Market Share by Country (2021-2032)
- Figure 55: Brazil Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 56: Argentina Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 57: Chile Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 58: Colombia Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 59: Peru Sustained Release Injectables Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 60: Sanofi Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 61: Novartis Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 62: Merck Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 63: Luye Pharma Group Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 64: Roche Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 65: Livzon Pharm Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 66: Eli Lilly Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 67: AstraZeneca Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 68: Xbrane Biopharma Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 69: Taiwan Liposome Company (TLC) Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 70: Recipharm AB Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 71: PhaseBio Pharmaceuticals Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 72: Pacira Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 73: OctoPlus Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 74: Oakwood Laboratories/PharmaSophia Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 75: NanOlogy Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 76: Janssen Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 77: Ipsen Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 78: InnoCore Pharmaceuticals Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 79: Enzon Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 80: Durect Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 81: Critical Pharmaceuticals Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 82: Camurus Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 83: Biomarin Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 84: Avadel Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 85: Aurobindo Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 86: Ascendis Pharma Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 87: AntriaBio Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 88: Amylin Pharmaceuticals Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)
- Figure 89: Alkermes Revenue Growth Rate in Sustained Release Injectables Business (2021-2026)